Navigation Links
Abaxis Reports Financial Performance with Record Revenues for the Second Quarter of Fiscal 2012
Date:10/25/2011

UNION CITY, Calif., Oct. 25, 2011 /PRNewswire/ -- ABAXIS, Inc. (NasdaqGS: ABAX), a medical products company manufacturing point-of-care blood analysis systems, today reported financial results for the second fiscal quarter ended September 30, 2011.

Record quarterly highlights include:

  • Revenues of $40.0 million, up 13% over last year's comparable quarter.
  • North America revenues of $32.0 million, up 8% over last year's comparable quarter.
  • Veterinary market sales of $31.5 million, up 18% over last year's comparable quarter.
  • Total medical and veterinary reagent disc sales of $22.8 million, up 18% over last year's comparable quarter.

  • Other quarterly highlights include:

  • Medical market sales of $7.3 million, up 7% over last year's comparable quarter.
  • Total medical and veterinary instrument sales of $8.8 million, up 15% over last year's comparable quarter.
  • Total medical and veterinary instrument sales of 1,227 units, up 24% over last year's comparable quarter.
  • Total medical and veterinary reagent disc sales of 1.8 million units, up 16% over last year's comparable quarter.

  • Quarterly Results:  For the fiscal quarter ended September 30, 2011, Abaxis reported revenues of $40.0 million, as compared with revenues of $35.3 million for the comparable period last year, an increase of 13 percent.
    Revenues from instruments, which include chemistry analyzers, hematology instruments, VSpro coagulation and specialty analyzers and i-STAT analyzers, increased by an aggregate of $1.1 million, or 15 percent, over the same period last year.  Revenues from consumables, which include reagent discs, hematology reagent kits, VSpro coagulation and specialty cartridges, i-STAT cartridges and rapid tests, increased by an aggregate of $4.2 million, or 17 percent, over the same period last year.
    Abaxis reported net income of $3.3 million for the fiscal quarter ended Se
    '/>"/>

    SOURCE ABAXIS, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9

    Related medicine technology :

    1. Abaxis to Report Second Quarter Fiscal Year 2012 Financial Results Tuesday, October 25, 2011
    2. Abaxis, Inc. to Present at CL Kings 9th Annual Best Ideas Conference 2011
    3. Abaxis to Present at 2011 Morgan Stanley Global Healthcare Unplugged Conference
    4. Abaxis Announces Stock Repurchase Program
    5. Abaxis Reports Financial Performance for the First Quarter of Fiscal 2012
    6. Abaxis to Report First Quarter Fiscal Year 2012 Financial Results Thursday, July 28, 2011
    7. Abaxis to Present at Jefferies 2011 Global Healthcare Conference
    8. Abaxis to Present at ThinkEquitys Second Annual Healthcare Conference
    9. Abaxis Receives Presidential "E" Award for Exports
    10. Abaxis, Inc. Awarded $650,000 from Kansas Bioscience Authority
    11. Abaxis, Inc. to Present at the Bank of America Merrill Lynch 2011 Health Care Conference
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:1/15/2014)... Ky. , Jan. 15, 2014  Manufacturers, suppliers ... must be able to protect their most important ... http://photos.prnewswire.com/prnh/20130716/CL46586LOGO ) Because of ... it steadfastly remains one of the most litigious ...
    (Date:1/15/2014)... 2014 MultiCell Technologies, Inc. (OTC Bulletin Board: ... application concerning composition of matter, biological targets, mechanism of ... death.  This patent application describes a ... molecules (VSRNAs) which interfere with the basic homeostatic cellular ...
    (Date:1/15/2014)... Jan. 15, 2014  According to Millennium Research Group ... intelligence, the United States ... markets will expand moderately through 2022, with embolization ... particular, increasing interest in drug-eluting beads (DEBs) and ...
    Breaking Medicine Technology:Intellectual Property Insurance for Medical-related Products and Services 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 3US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 2US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 3
    (Date:7/9/2014)... MA -- Vasectomy was associated with a small increased ... advanced or lethal prostate cancer according to a new ... researchers found that the association remained even among men ... of lethal cancer cannot be explained by diagnostic bias. ... date to look at the link between vasectomy and ...
    (Date:7/9/2014)... Susan Wakulich was told she had an aneurysm, she figured ... her. , "I was devastated," said Wakulich, who is 56 ... this was a serious diagnosis. Then I met Dr. Bernard ... a less invasive procedure. It was something I didn,t even ... a multi-center U.S. clinical trial to evaluate the safety and ...
    (Date:7/9/2014)... that captures heretofore hidden ways that cells are regulated, ... makes breast cancer cells more likely to metastasize. , ... in part by blocking two other proteins that are ... two disease processes could have unexpected ties. , ... of Nature , points to the possibility of ...
    (Date:7/9/2014)... into the metabolism of stromal support cells and immune ... these cell types in the development of diseases ... and cancer. That was the conclusion of a review ... the leading journal Nature . , Prof. Peter ... call. The metabolism of cancer cells has been examined ...
    (Date:7/9/2014)... that fecal transplantation is effective and safe for treating ... the result of a study led by Colleen Kelly, ... Medicine at The Women,s Medicine Collaborative. The study and ... print in the American Journal of Gastroenterology . ... , has increased to epidemic proportions over the past ...
    Breaking Medicine News(10 mins):Health News:Vasectomy may increase risk of aggressive prostate cancer 2Health News:New type of stent could help some brain aneurysm patients 2Health News:Protein pushes breast cancer cells to metastasize 2Health News:Protein pushes breast cancer cells to metastasize 3Health News:Wake-up call for more research into cell metabolism 2Health News:Women's Medicine Collaborative examines safety of fecal transplant to treat C. difficile 2
    ... effective, long-term treatment for trigeminal neuralgia: a painful condition ... sclerosis (MS). Radiation is noninvasive and has less negative ... follow-up in a study of its kind presented October ... American Society for Radiation Oncology (ASTRO). Multiple ...
    ... HealthDay Reporter , MONDAY, Oct. 25 (HealthDay News) -- ... infants will start sleeping through the night between 2 and ... longer, however, is for the baby,s eight hours of slumber ... study. "The most rapid changes in infant sleep were ...
    ... cancer drug could be produced cheaply and sustainably using stem ... isolated and grown stem cells from a yew tree whose ... The development could enable the compound to be produced on ... Scientists and engineers behind the development say the ...
    ... reason many smokers struggle to quit. According to new ... history of anxiety disorders are less likely to quit ... Center for Tobacco Research and Intervention (UW-CTRI), offered free ... , While overall quit rates for the study were ...
    ... By Kathleen Doheny HealthDay Reporter , MONDAY, Oct. ... with more than half of the segments in the heart,s main ... a new study shows. The good news? Other parts ... within three months or fewer after the run, the researchers found. ...
    ... HealthDay Reporter , SUNDAY, Oct. 24 (HealthDay News) -- Concussions ... Just last week, the National Football League announced it would ... result in head injuries. Now, a new 12-year study ... been sidelined significantly longer after concussions than they were in ...
    Cached Medicine News:Health News:Radiation therapy improves painful condition associated with multiple sclerosis 2Health News:Most Babies Start Sleeping Through Night at 2 to 4 Months 2Health News:Most Babies Start Sleeping Through Night at 2 to 4 Months 3Health News:Plant stem cells could be fruitful source of low-cost cancer drug 2Health News:Common anxiety disorders make it tougher to quit cigarettes 2Health News:Marathons Affect Heart, but Runners Bounce Back 2Health News:Marathons Affect Heart, but Runners Bounce Back 3Health News:NFL Players With Concussions Sidelined Longer: Study 2Health News:NFL Players With Concussions Sidelined Longer: Study 3
    ... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
    ... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
    ... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
    ... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
    Medicine Products: